.Pharmacolibrary.Drugs.ATC.J.J01XB02

Information

Polymyxin B is a polypeptide antibiotic primarily active against Gram-negative bacteria. It is used to treat severe infections caused by multidrug-resistant organisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii, and other carbapenem-resistant Enterobacteriaceae. The drug is reserved for infections where alternatives are not suitable due to its nephrotoxicity and neurotoxicity. Polymyxin B is still clinically used today, predominantly in hospital settings.

Pharmacokinetics

Adult critically ill patients, population pharmacokinetic analysis.

References

1. Kubin, CJ, et al., & Yin, MT (2018). Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. Antimicrobial agents and chemotherapy 62(3) –. DOI:10.1128/AAC.01493-17 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29311066

2. Hanafin, PO, et al., & Rao, GG (2023). A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 29(9) 1174–1181. DOI:10.1016/j.cmi.2023.05.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37217076

3. Wang, PL, et al., & Yang, J (2022). Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. The Journal of antimicrobial chemotherapy 77(11) 3000–3008. DOI:10.1093/jac/dkac265 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35924405

Revisions

• 06/2025 initial generated model